acquired egfr resistance: what are the current therapeutic strategies?
Published 10 years ago • 1.3K plays • Length 20:07Download video MP4
Download video MP3
Similar videos
-
21:09
mechanisms of resistance to egfr tki and new treatment strategies
-
18:06
egfr inhibitors in mutation ( ) patients: current therapeutic strategies in the frontline setting
-
26:27
novel egfr inhibitors in the setting of acquired resistance
-
44:03
egfr: the challenge of primary and secondary resistance
-
20:18
understanding, preventing, and delaying egfr resistance in the era of osimertinib
-
5:32
introduction to egfr inhibitors
-
34:15
keynote lecture 1: unraveling the taxonomy in gastric cancer
-
28:17
segment 1: egfr tkis in nsclc
-
20:27
managing egfr-resistant disease: t790 and beyond
-
3:07
third generation egfr tkis for acquired resistance
-
24:36
treatment options for egfr t790m negative acquired resistance
-
10:06
debate: what is the optimal timing for egfr-targeted therapy? - favor frontline therapy
-
20:35
tki-resistant egfr-mutant nsclc
-
1:48
acquired resistance to third-generation egfr tkis in nsclc
-
20:24
targeted treatment with egfr tkis: front line options
-
4:55
what is acquired resistance and how does it occur?
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
16:28
panel discussion: managing patients with acquired egfr resistance
-
3:48
mechanisms of resistance to upfront egfr-targeted therapy
-
18:44
2020 ttf egfr breakout piotrowska part 2 - current options upon acquired resistance to osimertinib
-
1:59
what is egfr and the egfr mutation?
-
11:23
2020 ttf egfr breakout piotrowska part 1 - current options upon acquired resistance to osimertinib